• 17 June, 2025

Novo Nordisk exits R&D in inflammatory disorders

September 03, 2014 | Wednesday | News | By BioSpectrum Bureau

Novo Nordisk exits R&D in inflammatory disorders

On September 2, 2014, Novo Nordisk officially announced its decision to discontinue all its R&D activities within inflammatory disorders.

The company said that it will increase its focus and efforts more within diabetes prevention and treatment, obesity and diabetes complications.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is India’s Integrated DigiTech targeting Affordable Healthcare Access?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy